¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"tumor specific antigen"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • retroperitoneal tumor
    Èĺ¹¸·Á¾¾ç, ¹è¸·µÚÁ¾¾ç
  • solid tumor
    °íÇüÁ¾¾ç
  • solid-cystic tumor
    °íÇü³¶¼ºÁ¾¾ç
  • spinal cord tumor
    ô¼öÁ¾¾ç
  • steroid cell tumor
    ½ºÅ×·ÎÀ̵弼Æ÷Á¾¾ç
  • stromal tumor
    °£ÁúÁ¾¾ç, ¹öÆÀÁúÁ¾¾ç
  • submucosal tumor
    Á¡¸·¹ØÁ¾¾ç, Á¡¸·ÇÏÁ¾¾ç
  • sebaceous tumor
    ÇÇÁö»ùÁ¾¾ç, ±â¸§»ùÁ¾¾ç
  • Sertoli-Leydig cell tumor
    ¼¼¸£Å縮¶óÀ̵ðÈ÷Á¾¾ç
  • sex cord-stromal tumor
    ¼º²ö±âÁúÁ¾¾ç, ¼º»è±âÁúÁ¾¾ç
  • smooth muscle tumor
    ÆòȰ±ÙÁ¾¾ç
  • virilizing tumor
    ³²¼ºÈ­Á¾¾ç
  • Wilms¡¯ tumor
    ºô¸§½ºÁ¾¾ç
  • antigen
    Ç׿ø
  • antigen analysis
    Ç׿øºÐ¼®
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • organoid tumor
    (¢¡teratoma) ±âÇüÁ¾
  • peripheral primitive neuroectodermal tumor
    ¸»ÃÊ¿ø½Ã½Å°æ¿Ü¹è¿±Á¾¾ç
  • phantom tumor
    ȯ°¢Á¾¾ç, ȯ»óÁ¾¾ç
  • phyllodes tumor
    ¿±»óÁ¾¾ç
  • polypoid tumor
    Æú¸³Á¾¾ç
  • primitive neuroectodermal tumor
    ¿ø½Ã½Å°æ¿Ü¹è¿±Á¾¾ç
  • tumor control probability
    Á¾¾ç¾ïÁ¦À²
  • renin-secreting juxtaglomerular tumor
    ·¹´ÑºÐºñÅ丮°çÁ¾¾ç
  • retroperitoneal tumor
    ¹è¸·µÚÁ¾¾ç, º¹¸·µÚÁ¾¾ç
  • tumor regeneration
    Á¾¾çÀç»ý
  • sebaceous tumor
    ÇÇÁö»ùÁ¾¾ç
  • sex cord-stromal tumor
    (¢¡stromal tumor) ¼º²ö°£ÁúÁ¾¾ç, ³­¼Ò¹öÆÀÁúÁ¾¾ç
  • smooth muscle tumor
    ÆòȰ±ÙÁ¾¾ç
  • solid tumor
    °íÇüÁ¾¾ç
  • solid-cystic tumor
    °íü³¶¼ºÁ¾¾ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • D antigen
    D Ç׿ø
  • D antigen
    DÇ׿ø
  • D-related antigen
    D-°ü·ÃÇ׿ø
  • DP antigen
    DPÇ׿ø
  • DQ antigen
    DQÇ׿ø
  • DR antigen
    DRÇ׿ø
  • Diego antigen
    µð¿¡°íÇ׿ø
  • EB nuclear antigen(EBNA0
    EB ¹ÙÀÌ·¯½º ÇÙÇ׿ø
  • EB nuclear antigen (EBNA)
    EB¹ÙÀÌ·¯½º ÇÙÇ׿ø
  • EBV capsid antigen
    EB¹ÙÀÌ·¯½º ĸ½Ãµå Ç׿ø
  • EBV capsid antigen (VCA)
    EB¹ÙÀÌ·¯½º ĸ½ÃµåÇ׿ø
  • EBV membrane antigen
    EB¹ÙÀÌ·¯½º ¸·Ç׿ø
  • EBV membrane antigen (MA)
    EB¹ÙÀÌ·¯½º ¸·Ç׿ø
  • Forssman antigen
    Æ÷½º¸¸Ç׿ø
  • Fy antigen/antibody
    Fy Ç׿ø/Ç×ü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • specific inflammation
    ƯÀ̼º¿°(¡­àõæú)
  • specific inhibitor
    ƯÀÌÀû ¾ïÁ¦Á¦.
  • specific ionization
    ƯÀÌÀÌ¿ÂÈ­.
  • specific marriage rate
    ƯÁ¤°áÈ¥À²(Ì¬Ëø Ë­Ì´Ëô).
  • specific morbidity rate
    ƯÁ¤ÀÌȯÀ²(Ì¬Ëø ËöÌ·Ëô).
  • specific mortality rate
    ƯÁ¤»ç¸Á·ü(Ì¬Ëø Ë×ËÎËô).
  • specific muscle force
    ºñ±Ù·Â(ÝïÐÉæ³).
  • specific muscle force
    ºñ±Ù ·Â(ÝïÐÉæ³).
  • specific nerve energy
    Ư¼ö½Å°æ(÷åâ¨ãêÌè) ¿¡³ÊÁö.
  • specific nuclei
    Ư¼öÇÙ.
  • specific pathogen free animal
    ƯÁ¤¹«±Õµ¿¹°(÷åïÒÙíжÔÑÚª).
  • specific pathogen free animal
    ƯÁ¤¹«±Õµ¿¹°(÷åïÒÙíжÔÑÚª).
  • specific personality disorder
    ƯÁ¤ ÀΰÝÀå¾Ö
  • specific phobia
    ƯÁ¤ °øÆ÷Áõ(º´)
  • specific photoelectricity
    ºñ±¤Àü´É(ÝïÎà ï³Òö).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • tissue polypeptide antigen
    Á¶Á÷(ðÚòÄ)Æú¸®ÆéŸÀ̵å Ç׿ø (ù÷ê«)
  • tolerogenic antigen
    ³»¼º»ý¼º Ç׿ø (Ò±àõßæà÷ù÷ê«)
  • transplantation antigen
    ÀÌ½Ä Ç׿ø(ì¹ãÕù÷ê«)
  • V antigen
    V Ç׿ø(ù÷ê«)
  • Vi antigen
    Vi Ç׿ø (ù÷ê«)
  • virus antigen
    ¹ÙÀÌ·¯½º Ç׿ø (ù÷ê«)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
APS adenosine phosphosulfate; American Pain Society; American Pediatric Society; American Physiological ...
GAG glycosaminoglycan; group-specific antigen gene
MBLA methylbenzyl linoleic acid; mouse-specific bone-marrow-derived lymphocyte antigen
MSBLA mouse-specific B lymphocyte antigen
MSLA mouse-specific lymphocyte antigen
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
BAP Bone specific alkaline phosphatase
CSS Cause specific survival
CNSLD Chronic non-specific lung disease
DSS Disease specific survival
DST Donor specific blood transfusion
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • broad based tumor
    ±âÀúºÎ°¡ ³ÐÀº Á¾¾ç
  • calcified epithelial odontogenic tumor
    ¼®È¸È­ »óÇǼº Ä¡¼º Á¾¾ç
  • carotid body tumor
    °æµ¿¸Æ ¼Òü Á¾¾ç
  • cartilaginous tumor
    ¿¬°ñ¼º Á¾¾ç
    Á¶ÀýÇÒ ¼ö ¾øÀ» Á¤µµ·Î °è¼Ó ÁøÇàµÇ´Â ¼¼Æ÷ºÐ¿­¿¡ ÀÇÇÑ ¿¬°ñ Á¶Á÷ÀÇ »õ·Î¿î Áõ½Ä ¹× Áõ´ë.
  • cavernous tumor
    ÇØ¸é»ó Á¾¾ç, ÇØ¸éÁ¾
    µ¿ÀǾî=cavenoma.
  • central giant cell tumor
    Á߽ɼº °Å´ë ¼¼Æ÷ ¾ÏÁ¾
  • cerebellopontine tumor
    ¼Ò³ú ±³°¢ Á¾¾ç
  • children tumor
    ¼Ò¾Æ ¾Ï
    ¼Ò¾Æ¿¡°Ô »ý±â´Â ¾Ç¼º Á¾¾ç. ¼Ò¾Æ¿¡°Ô´Â À§¾Ï, Æó¾Ï, Àڱà ¾Ï µîÀº °ÅÀÇ º¼ ¼ö ¾øÁö¸¸, ±Þ¼º ¹éÇ÷º´, ¾Ç¼º ¸²ÇÁÁ¾, ³úÁ¾¾ç, °íȯ žƼº ¾Ï, ½Å°æ¾Æ¼¼Æ÷Á¾, °£¾Ï, °ñ À°Á¾, ºñ·ç½º¼º Á¾¾ç µîÀÌ ¸¹´Ù.
  • congenital intracranial tumor
    ¼±Ãµ¼º µÎ°³³» Á¾¾ç
  • delta cell tumor
    µ¨Å¸ ¼¼Æ÷ Á¾¾ç
    ¼Ò¸¶Å佺ŸƾÀ» ºÐºñÇÏ´Â Á¾¾çÀ¸·Î ¼Ò¸¶Å佺ŸƾÁ¾
  • dermoid tumor
    À¯ÇÇÁ¾
  • dysembryoplastic neuroepithelial tumor
    ÀÌÇü¼º ¹è¾Æ¼º ½Å°æ»óÇÇÁ¾
    ¾à¹° Ä¡·á¿¡ ¹ÝÀÀÇÏÁö ¾ÊÀº ºÎºÐ º¹ÇÕÇü °£ÁúÀ» Ư¡ÀûÀ¸·Î µ¿¹ÝÇÏ´Â Á¾¾çÀ¸·Î¼­ 20¼¼ ¹Ì¸¸ÀÇ Ã»¼Ò³â±â¿¡ Áõ»óÀÌ ½ÃÀ۵ȴÙ. ÃøµÎ¿±¿¡ È£¹ßÇϸç ÀüµÎ¿±À̳ª µÎÁ¤¿±¿¡¼­ ¹ß»ýµÇ±âµµ ÇÑ´Ù. ´Ù°áÀý¼º Á¾±«·Î¼­ ÇÌÁö±³Á¾¼º ¼¼Æ÷µéÀÌ Á¡¾×¼º ±âÁú°ú ÇÔ²² ³ªÅ¸³­´Ù. ÀÌ·¯ÇÑ ÇÌÁö±³Á¾¼º ¼¼Æ÷µéÀº ¸é¿ªÁ¶Á÷È­ÇÐÀû ¶Ç´Â ÀüÀÚÇö¹Ì°æÀû °üÂû»ó ¼º»ó ¼¼Æ÷, ÇÌÁö±³ ¼¼Æ÷, ½Å°æ¿ø ¼¼Æ÷µéÀÌ ¼¯¿©Á® ÀÖÀ½ÀÌ Áõ¸íµÇ¾ú´Ù. ¾ç¼º Á¾¾çÀ̸ç ÁÖÀ§¿¡ ´ë³ú ÀÌÇü¼ºÁõÀ» ÈçÈ÷ µ¿¹ÝÇÑ´Ù.
  • endoaermal sinus tumor
    ³»¹è¿±µ¿ Á¾¾ç
    ¹ß»ý ºóµµ°¡ ³·Áö¸¸ ³­¼ÒÀÇ ¾Ç¼º »ý½Ä ¼¼Æ÷Á¾ Áß¿¡ µÎ ¹øÂ°·Î ÈçÇϰí Àüü ³­¼Ò Á¾¾çÀÇ 1% Á¤µµ¸¦ Â÷ÁöÇÑ´Ù. Á¶Á÷ÇÐÀûÀ¸·Î ³­È² ³¶ÀÇ ³»¹è¿± µ¿À» ´à¾Ò´Ù ÇÏ¿© ³­È² ³­ Á¾¾ç ¶Ç´Â ³»¹è¿±µ¿ Á¾¾çÀ̶ó°í ÇÑ´Ù. ÀÌ Á¾¾çÀº ÁÖ·Î ¾î¸°ÀÌ¿Í ÀþÀº ¿©¼º¿¡ È£¹ßÇÏ°í Æò±Õ ¿¬·ÉÀº 19¼¼ÀÌ´Ù. Çö¹Ì°æÀûÀ¸·Î ÀÛÀº ´Ù¹æ¼º ³¶ ±¸Á¶¸¦ °®´Â °íÇü¼º Á¾¾çÀÌ°í ´ë°³ ÀÏÃø¼ºÀÌ´Ù. ¾û¼ºÇÑ ¸Á»óÇü ¾ç»ó, Schiller-¿·¹Ì ¼Òü¸¦ Çü¼ºÇÏ´Â À¯µÎ ¾ç»ó, ´Ù¼Ò ³¶Æ÷¼º ³­È² ¾ç»ó, °íÇü¼º ¾ç»ó µîÀÌ È¥ÇÕµÇ¾î ³ª¿À°í ±¸¼º ¼¼Æ÷´Â ¹Ì¼º¼÷ ¹è ¼¼Æ÷ÀÇ Æ¯Â¡À» °®´Â´Ù. ¼¼Æ÷Áú ¾ÈÀ̳ª ¼¼Æ÷ ¹Û¿¡ À¯¸®Áú ±¸»óüµéÀÌ °üÂûµÇ´Âµ¥ À̵éÀº ¸é¿ª È¿¼Ò ¿°»ö¿¡¼­ ¾ËÆÄ ÅÂ¾Æ ´Ü¹é
  • endometrioid tumor
    Àڱà ³»¸·¾ç Á¾¾ç
  • exophytic mucosal tumor
    ¿ÜÇ⼺ Á¡¸· Á¾¾ç
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
law of specific nerve energies Each type of sensory nerve ending, however stimulated (electrically, mechanically, etc.), gives rise to its own specific sensation; moreover, each type of sensation depends not upon any special character of the different nerves but upon the part of the brain in which their fibres terminate.
Synonym: law of specific nerve energies.
(05 Mar 2000)
lymphocyte specific protein tyrosine kinase p56(lck) <enzyme> This enzyme is a lymphoid specific src family tyrosine kinase that is critical for T-cell development and activation. Lck is associated with the cytoplasmic domains of CD4, CD8 and the beta-chain of the il-2 receptor, and is thought to be involved in the earliest steps of tcr-mediated T-cell activation.
Registry number: EC 2.7.11.-
(12 Dec 1998)
acetone-insoluble antigen A diphosphatidyl glycerol that is found in the membrane of Treponema pallidum and is the antigen detected by the Wasserman test for syphilis.
(18 Nov 1997)
allogeneic antigen Genetic variations of the same antigens within a given species.
(05 Mar 2000)
antigen Virus coded cell surface antigens that appear soon after the infection of a cell by virus, but before virus replication has begun.
See: early gene.
(18 Nov 1997)
antigen-antibody complex The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes immune complex diseases. If the antigen is polyvalent the complex may be insoluble.
Immune complexes activate complement through the classical pathway.
See: glomerulonephritis, Arthus reaction, type III hypersensitivity.
(12 Dec 1998)
antigen-antibody reaction The phenomenon, occurring in vitro or in vivo, of antibody combining with antigen of the type that stimulated the formation of the antibody, thereby resulting in agglutination, precipitation, complement fixation, greater susceptibility to ingestion and destruction by phagocytes, or neutralization of exotoxin.
See: skin test.
(05 Mar 2000)
antigen-binding site <immunology> In immune network theory, an idiotope, an antigenic site of an antibody that is responsible for that antibody binding to an antigenic determinant (epitope).
Also used of the site on a ligand molecule to which a cell surface receptor binds.
(18 Nov 1997)
antigen-combining site See: paratope.
(05 Mar 2000)
antigen excess In a precipitation test, the presence of uncombined antigen above that required to combine with all of the antibody; precipitation may be inhibited because the presence of excess antigen gives rise to soluble antigen-antibody complexes, in vivo the resultant antigen-antibody interaction in such an antigen excess may give rise to immune complexes, which have a potential to induce cellular damage; such injury underlies the pathologic changes seen in certain immune complex diseases.
(05 Mar 2000)
antigen interferon <cytokine> Interferon elaborated by T lymphocytes in response to either specific antigen or mitogenic stimulation.
This type II interferon can be produced by recombinant DNA technology and is similar to the interferon secreted by lymphocytes and has antiviral and antineoplastic activity.
Synonym: antigen interferon, immune interferon.
Pharmacological action: antineoplastic agent, antiviral agents.
(20 Sep 2002)
antigen p150,95 A major adhesion-associated heterodimer molecule expressed by human monocytes, granulocytes, nk cells, and some lymphocytes. The alpha subunit is the CD11c antigen (also called leu-m5), a surface antigen expressed on some myeloid cells. The beta subunit is the CD18 antigen (antigens, CD18). The p150,95 antigen has been shown to play an important role in cell-cell and cell-substrate adhesive interactions.
(12 Dec 1998)
antigen presentation A cell that carries on its surface antigen bound to MCH Class I or Class II molecules and presents the antigen in this context to T-cells. Includes macrophages, endothelium, dendritic cells and Langerhans cells of the skin.
See: MHC restriction, histocompatibility antigens.
(18 Nov 1997)
antigen presenting cell A cell that carries on its surface antigen bound to MCH Class I or Class II molecules and presents the antigen in this context to T-cells. Includes macrophages, endothelium, dendritic cells and Langerhans cells of the skin.
See: MHC restriction, histocompatibility antigens.
(18 Nov 1997)
antigen-presenting cells Immunocompetent cells, usually ia positive, that mediate the cellular immune response by processing and presenting antigens or mitogens which stimulate T-cell activation.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
ÅëÇÕ°Ë»ö ¿Ï·á